+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience



Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience



BrachyTherapy 15(2): 177-184



To evaluate the incidences of vaginal recurrence and toxicity after vaginal brachytherapy in Stage I-II endometrial cancer. Between 2003 and 2012, 150 high-intermediate-risk Stage I and 7 Stage II patients, median age 64 years, underwent surgery, with or without lymphadenectomy, and 3D brachytherapy: 7 Gy, at 5 mm depth from applicator surface, for 3-week fractions. The effects of age, grading, number of excised lymph nodes and pathologic stage on loco-regional relapse (LRR), metastases, and tumor-related death were investigated. Vaginal toxicity was evaluated during followup visits. At 83 months of median followup, 144 patients were disease free, 2 in relapse, 7 deceased from disease, and 4 from other causes. One vaginal (0.6%), five nodal (3.2%), three pelvic over the vaginal cuff (1.9%), and one distant recurrences were seen (0.6%). The 5-year probability of LRR-free, distant metastasis-free and cause-specific survivals for all patients were 93.6% (95% confidence interval [CI]: 88.1-96.7), 97.8% (95% CI: 93.2-99.3), and 96.5% (95% CI: 93.5-99.5) and for Stage I 95.7% (95% CI: 92.2-9.1), 99.3% (95% CI: 98.0-100), and 97.7% (95% CI: 95.2-100), respectively. At multivariate analysis, Stage II disease and more than 12 lymph nodes sampled were associated with LRR (hazard ratio [HR]: 3.88; 95% CI: 1.390-10.878; p = 0.010 and HR: 6.952; 95% CI: 1.591-30.385; p = 0.010) and Stage II with metastasis and tumor-related death (HR: 23.057; 95% CI: 2.296-231.485; p = 0.008 and HR: 4.324; 95% CI: 1.223-15.290; p = 0.023). Vaginal acute and chronic toxicity was 16% and 55.4%, respectively, all only Grades 1-2. For high-to-intermediate-risk Stage I endometrial cancer, 3D vaginal brachytherapy achieved good local control and low toxicity. In Stage II, patients brachytherapy could be administered after complete surgical staging.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058712364

Download citation: RISBibTeXText

PMID: 26727332

DOI: 10.1016/j.brachy.2015.10.010


Related references

Vaginal Vault Brachytherapy Alone As Adjuvant Treatment For Node-Negative Stage Ii Endometrial Cancer Manitoba Experience. Radiotherapy and Oncology 92: S45-S46, 2009

Adjuvant Vaginal Cuff Brachytherapy for High-Risk, Early Stage Endometrial Cancer: A Single-Institution Experience. BrachyTherapy 13: S77-S78, 2014

American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. BrachyTherapy (): -, 2016

Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?. BrachyTherapy 18(4): 453-461, 2019

Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy. BrachyTherapy 16(6): 1152-1158, 2017

EP-1652: Feasibility, tolerance and toxicity of adjuvant vaginal brachytherapy in endometrial cancer. RadioTherapy and Oncology 115: S905-S906, 2015

Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 62(5): 1379-1384, 2005

Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecologic Oncology 97(3): 887-892, 2005

Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecologic Oncology 133(3): 494-498, 2014

Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer. Gynecologic Oncology 144(3): 515-523, 2017

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. Journal of Contemporary BrachyTherapy 6(3): 262-270, 2014

Vaginal cuff HDR brachytherapy alone is sufficient adjuvant treatment for patients with surgical stage I endometrial cancer. International Journal of Radiation Oncology*biology*physics 60: S213-S214, 2004

Adjuvant high dose rate vaginal cuff brachytherapy for early stage endometrial cancer. International Journal of Radiation Oncology Biology Physics 39(2 Suppl. ): 296, 1997

A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer. Gynecologic Oncology 127(2): 351-355, 2012

Can combination vaginal HDR brachytherapy and lymphadenectomy replace adjuvant pelvic XRT for early stage endometrial cancer?. International Journal of Radiation Oncology*biology*physics 42(1-Supp-S1): 318-0, 1998